Development and Validation of a Tumour Oxygenation Monitoring Probe
Status
Conditions
Treatments
Details and patient eligibility
About
Laboratory based study in which novel tissue oxygenation probe with the potential provide novel means for assessing response to cancer treatment will be developed and validated.
Full description
Tumour hypoxia is feature common to most solid tumours, with significant implications in tumour aggressiveness, metastatic potential and response to therapy. Tumour oxygenation monitoring is likely, therefore, to provide a valuable adjunct in risk stratification and treatment response monitoring.
Diffuse reflectance spectroscopy (DRS) utilises the differing absorption of oxygenated as compared to deoxygenated haemoglobin to provide an accurate measure of tissue oxygenation.
This project aims to develop and validate a tissue oxygenation probe for cancer monitoring. Using the clinical paradigms of rectal and breast cancer, anonymised MRIs of cancer sufferers will guide simulations of tissue optical properties to develop a DRS probe. The 3D reconstructed sans will then be used to 3D print tissue phantom models on which the DRS probe will be validated against reference bench top analysers.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- MRIs from Breast or Rectal Cancer patients (10 of each)
- Locally advanced Cancers (Stage 2 or 3)
- Patients who went on to receive neoadjuvant chemoradiotherapy.
- Anonymised scans
Exclusion criteria
- MRIs from patients under the age of 18, or older than 99 years old will be excluded.
- MRIs from patients who did not receive neoadjuvant therapy for cancer will be excluded.
Trial design
20 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Simon D Dryden, MBChB, MPH
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal